Imvax

Imvax is a clinical-stage biotechnology company with a unique platform technology focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax's portfolio includes several programs designed to stimulate a patient's immune system against the entire antigen signature of their tumor. Imvax's most advanced program is IGV-001 for the treatment of glioblastoma.